TD Cowen's 46th Annual Health Care Conference

Pharma's Policy Reckoning

The pharmaceutical sector enters March 2026 amid a whirlwind of regulatory upheaval. Just weeks earlier, on February 3, President Trump signed legislation overhauling pharmacy benefit managers (PBMs), intermediaries that negotiate drug prices between insurers and manufacturers. This reform demands full rebate pass-through to plans and flat-fee compensation models, dismantling the opaque rebate systems that have long buoyed industry profits. Simultaneously, FDA Commissioner Marty Makary's push for streamlined approvals—requiring only one pivotal study instead of two—and expanded over-the-counter access signals a bid to hasten innovation and cut costs, but it raises questions about long-term safety monitoring.

These changes collide with broader economic pressures, including proposed tariffs on imported active pharmaceutical ingredients (APIs) under the Trump administration's 'America First' agenda. With over 80% of APIs sourced from abroad, particularly China and India, tariffs could inflate production costs significantly, affecting everything from generic drugs to cutting-edge biologics. Companies like Eli Lilly, set to present at the conference, face acute impacts given their reliance on global supply for blockbuster GLP-1 agonists used in diabetes and obesity treatment. The stakes extend to patients, as higher costs may translate to restricted access or elevated insurance premiums, exacerbating affordability issues that already see one in four Americans skipping doses due to expense.

Beyond immediate financial hits, the reforms spotlight trade-offs often overlooked in mainstream discourse. Faster approvals might flood the market with therapies, but they could strain post-market surveillance systems, potentially leading to recalls or undetected side effects years down the line. Tariff-driven reshoring promises domestic job creation—estimated at 50,000 new positions—but it demands massive capital outlays amid workforce shortages in specialized manufacturing. Tensions brew between Big Pharma and PBMs, with the latter facing federal oversight that could curb their market power, yet manufacturers worry about squeezed margins without alternative revenue streams. Non-obvious angles include the ripple effects on biotech startups, which rely on M&A for exits; heightened regulatory scrutiny might deter acquisitions, stalling innovation in areas like gene therapy.

Concrete deadlines loom large. PBM transparency rules kick in January 2027, giving firms scant months to renegotiate contracts worth trillions. Tariff implementations, potentially phased from mid-2026, carry consequences like supply disruptions that could echo the 2022 shortages of critical antibiotics. Risks of inaction are stark: companies ignoring reshoring might face 10-25% duties, eroding competitiveness, while those pivoting too hastily risk overcapacity if global tensions ease. In oncology, where patent cliffs threaten $180 billion in sales by 2030, the conference's timing aligns with pivotal decisions on pipeline prioritization amid these headwinds.